Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia
Jörge E. Cortes(Augusta University Health), Mark J. Levis(Sidney Kimmel Cancer Center), Alan K. Burnett(Cardiff University), Sabine Käyser(German Cancer Research Center), Björn Steffen(Goethe University Frankfurt), Alexander E. Perl(University of Pennsylvania), Denise Trone(Unknown), Philippe Rousselot(Université Paris-Saclay), Elihu H. Estey(University of Washington), Giovanni Martinelli(University of Bologna), Hervé Dombret(University of London Institute in Paris), Guy Gammon(Unknown), Eugen Leo(Urologische Klinik München)
Cited by 121
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k